ErbelRAboyansVBoileauC. ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873–2926.
2.
DavisFMRateriDLDaughertyA. Mechanisms of aortic aneurysm formation: translating preclinical studies into clinical therapies. Heart. 2014;100(19):1498–1505.
3.
MussaFF. Screening for abdominal aortic aneurysm. J Vasc Surg. 2015;62(3):774–778.
4.
LiXZhaoGZhangJDuanZXinS. Prevalence and trends of the abdominal aortic aneurysms epidemic in general population--a meta-analysis. PLoS One. 2013;8(12):e81260.
5.
FlemingCWhitlockEPBeilTLLederleFA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142(3):203–211.
6.
NormanPEJamrozikKLawrence-BrownMM. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ. 2004;329(7477):1259.
7.
LederleFAJohnsonGRWilsonSE. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126(6):441–449.
8.
LederleFAWilsonSEJohnsonGR; Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346(19):1437–1444.
9.
United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346(19):1445–1452.
10.
MollFLPowellJTFraedrichG; European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011;41(suppl 1):s1–s58.
11.
TsimikasSWilleitPWilleitJ. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60(21):2218–2229.
12.
KronenbergFUtermannG. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273(1):6–30.
13.
KamstrupPRTybjaerg-HansenANordestgaardBG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146–1156.
14.
van DijkRAKolodgieFRavandiA. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012;53(12):2773–2790.
15.
WilleitPKiechlSKronenbergF. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851–860.
16.
ScipioneCASayeghSERomagnuoloR. Mechanistic insights into lipoprotein(a)-induced interleukin-8 expression: a role for oxidized phospholipid modification of apolipoprotein(a). J Lipid Res. 2015;56(12):2273–2285.
17.
TsimikasSDuffGWBergerPB. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014;63(17):1724–1734.
18.
BoffaMBKoschinskyML. Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?J Lipid Res. 2016;57(5):745–757.
19.
NorrgardOAngquistKADahlenG. High concentrations of Lp(a) lipoprotein in serum are common among patients with abdominal aortic aneurysms. Int Angiol. 1988;7(1):46–49.
20.
PurushothamanKRPurushothamanMLevyAP. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol. 2012;60(2):112–119.
21.
KotaniKSahebkarASerbanMC; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: A systematic review and meta-analysis. Angiology. 2017;68(2):99–108.
TsimikasSBergmarkCBeyerRW. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360–370.
24.
TsimikasSWitztumJLMillerER; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110(11):1406–1412.
25.
MullerNSchulteDMTurkK. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015;56(5):1034–1042.
26.
YeangCHungMYByunYS. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a). J Clin Lipidology. 2016;10(3):594–603.
27.
BertoiaMLPaiJKLeeJH. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013;61(21):2169–2179.
28.
HelgadottirAGretarsdottirSThorleifssonG. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60(8):722–729.
29.
NordestgaardBGChapmanMJRayK; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
30.
DavidsonMHBallantyneCMJacobsonTA. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338–367.
